-
1
-
-
27744472015
-
Use of preclinical assays to predict risk of drug-induced torsades de pointes
-
DOI 10.1016/j.hrthm.2004.10.032, PII S1547527104007635
-
Belardinelli, L., Shryock, J. C., Wu, L. and Song, Y. (2005). Use of preclinical assays to predict risk of drug-induced torsades de pointes. Heart Rhythm. 2, S16-S22. (Pubitemid 41600827)
-
(2005)
Heart Rhythm
, vol.2
, Issue.11 SUPPL. 2
-
-
Belardinelli, L.1
Shryock, J.C.2
Wu, L.3
Song, Y.4
-
2
-
-
27744587040
-
Clinical trial design to evaluate the effects of drugs on cardiac repolarization: Current state of the art
-
Camm, A. J. (2005). Clinical trial design to evaluate the effects of drugs on cardiac repolarization: current state of the art. Heart Rhythm. 2, S23-S29.
-
(2005)
Heart Rhythm
, vol.2
-
-
Camm, A.J.1
-
3
-
-
33644828344
-
In vitro and in vivo models for testing arrhythmogenesis in drugs
-
Carlsson, L. (2006). In vitro and in vivo models for testing arrhythmogenesis in drugs. J. Internal. Medicine. 259, 70-80.
-
(2006)
J. Internal. Medicine
, vol.259
, pp. 70-80
-
-
Carlsson, L.1
-
4
-
-
50049083789
-
The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes
-
Carlsson, L. (2008). The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes Pharmacol. Ther. 119, 160-167.
-
(2008)
Pharmacol. Ther.
, vol.119
, pp. 160-167
-
-
Carlsson, L.1
-
5
-
-
0034231822
-
Drugs that prolong QT interval as an unwanted effect: Assessing their likelihood of inducing hazardous cardiac dysrhythmias
-
Cavero, I., Mestre, M., Guillon, J. M. and Crumb, W. (2003). Drugs that prolong QT interval as an unwanted effect: Assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin. Pharmacother. 1, 947-973.
-
(2003)
Expert Opin. Pharmacother
, vol.1
, pp. 947-973
-
-
Cavero, I.1
Mestre, M.2
Guillon, J.M.3
Crumb, W.4
-
6
-
-
33947540277
-
Preclinical cardio-safety assessment of torsadogenic risk and alternative methods to animal experimentation: The inseparable twins
-
Dumotier, B. M. and Georgieva, A. V. (2007). Preclinical cardio-safety assessment of torsadogenic risk and alternative methods to animal experimentation: the inseparable twins. Cell Biol. Toxicol. 23, 293-302.
-
(2007)
Cell Biol. Toxicol.
, vol.23
, pp. 293-302
-
-
Dumotier, B.M.1
Georgieva, A.V.2
-
7
-
-
63649131984
-
Toxicology assessment of fluoroquinolones: A case study
-
Sietsema, W. K. and Schwen R., Eds. FDA news, Falls Church, USA.
-
Furuhama, K. (2007). Toxicology assessment of fluoroquinolones: A case study. In Nonclinical Drug Safety Assessment: Practical Considerations for Successful Registration (Sietsema, W. K. and Schwen R., Eds.), pp 571-588. FDA news, Falls Church, USA.
-
(2007)
Nonclinical Drug Safety Assessment: Practical Considerations for Successful Registration
, pp. 571-588
-
-
Furuhama, K.1
-
8
-
-
50049128135
-
Torsades de pointes liability inter-model comparisons: The experience of the QT PRODACT initiative
-
Hashimoto, K. (2008). Torsades de pointes liability inter-model comparisons: The experience of the QT PRODACT initiative. Pharmacol. Ther. 119, 195-198.
-
(2008)
Pharmacol. Ther.
, vol.119
, pp. 195-198
-
-
Hashimoto, K.1
-
9
-
-
33747887172
-
ILSI-HESI cardiovascular safety subcommittee initiative: Evaluation of three non-clinical models of QT prolongation
-
DOI 10.1016/j.vascn.2006.05.001, PII S1056871906000608
-
Hanson, L. A., Bass, A. S., Gintant, G., Mittelstadt, S., Rampe, D. and Thomas, K. (2006). ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. J. Pharmacol. Toxicol. Methods. 54, 116-129. (Pubitemid 44293425)
-
(2006)
Journal of Pharmacological and Toxicological Methods
, vol.54
, Issue.2
, pp. 116-129
-
-
Hanson, L.A.1
Bass, A.S.2
Gintant, G.3
Mittelstadt, S.4
Rampe, D.5
Thomas, K.6
-
10
-
-
33644524405
-
Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? a review of emerging trends
-
DOI 10.1016/j.vascn.2005.07.003, PII S1056871905000936
-
Hoffmann, P. and Warner, B. (2006). Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J. Pharmacol. Toxicol. Methods. 53, 87-105. (Pubitemid 43295657)
-
(2006)
Journal of Pharmacological and Toxicological Methods
, vol.53
, Issue.2
, pp. 87-105
-
-
Hoffmann, P.1
Warner, B.2
-
11
-
-
33746294441
-
Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias
-
DOI 10.1016/j.hrthm.2006.04.021, PII S1547527106014627
-
Liu, T., Brown, B. S., Wu, Y., Antzelevitch, C., Kowey, P. R. and Yan, G. X. (2006). Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm. 3, 948-956. (Pubitemid 44103507)
-
(2006)
Heart Rhythm
, vol.3
, Issue.8
, pp. 948-956
-
-
Liu, T.1
Brown, B.S.2
Wu, Y.3
Antzelevitch, C.4
Kowey, P.R.5
Yan, G.-X.6
-
12
-
-
48149084580
-
Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines
-
Lu, H. R., Vlaminckx, E., Hermans, A. N., Rohrbacher, J., Van, Ammel. K., Towart. R., Pugsley, M. and Gallacher, D. J. (2008). Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. Br. J. Pharmacol. 154, 1427-1438.
-
(2008)
Br. J. Pharmacol.
, vol.154
, pp. 1427-1438
-
-
Lu, H.R.1
Vlaminckx, E.2
Hermans, A.N.3
Rohrbacher, J.4
Van Ammel, K.5
Towart, R.6
Pugsley, M.7
Gallacher, D.J.8
-
13
-
-
0036784524
-
Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: Fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes
-
DOI 10.1124/jpet.102.037911
-
Milberg, P., Eckardt, L., Bruns, H. J., Biertz, J., Ramtin, S., Reinsch, N., Fleischer, D., Kirchhof, P., Fabritz, L., Breithardt, G. and Haverkamp, W. (2002). Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: Fast Phase 3 repolarization prevents early after depolarizations and torsade de pointes J. Pharmacol. Exper. Ther. 303, 218-225. (Pubitemid 35056471)
-
(2002)
Journal of Pharmacology and Experimental Therapeutics
, vol.303
, Issue.1
, pp. 218-225
-
-
Milberg, P.1
Eckardt, L.2
Bruns, H.-J.3
Biertz, J.4
Ramtin, S.5
Reinsch, N.6
Fleischer, D.7
Kirchhof, P.8
Fabritz, L.9
Breithardt, G.10
Haverkamp, W.11
-
14
-
-
50049111108
-
The canine model with chronic, complete atrio-ventricular block
-
Oros, A., Beekman, J. D. and Vos, M. A. (2008). The canine model with chronic, complete atrio-ventricular block. Pharmacol Ther. 119, 168-178.
-
(2008)
Pharmacol Ther.
, vol.119
, pp. 168-178
-
-
Oros, A.1
Beekman, J.D.2
Vos, M.A.3
-
15
-
-
48149115666
-
Strategies to reduce the risk of drug-induced QT interval prolongation: A pharmaceutical company perspective
-
Pollard, C. E., Valentin, J. P. and Hammond. T. G. (2008). Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective. Br. J. Pharmacol. 154, 1538-1543.
-
(2008)
Br. J. Pharmacol.
, vol.154
, pp. 1538-1543
-
-
Pollard, C.E.1
Valentin, J.P.2
Hammond, T.G.3
-
16
-
-
0344492207
-
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development
-
DOI 10.1016/S0008-6363(02)00846-5
-
Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., Siegl, P. K., Strang, I., Sullivan, A. T., Wallis, R., Camm, A. J. and Hammond, TG. (2003). Relationship between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32-45. (Pubitemid 36351620)
-
(2003)
Cardiovascular Research
, vol.58
, Issue.1
, pp. 32-45
-
-
Redfern, W.S.1
Carlsson, L.2
Davis, A.S.3
Lynch, W.G.4
MacKenzie, I.5
Palethorpe, S.6
Siegl, P.K.S.7
Strang, I.8
Sullivan, A.T.9
Wallis, R.10
Camm, A.J.11
Hammond, T.G.12
-
17
-
-
48149111313
-
Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts
-
Sugiyama, A. (2008) Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br. J. Pharmacol. 154, 1528-1537.
-
(2008)
Br. J. Pharmacol.
, vol.154
, pp. 1528-1537
-
-
Sugiyama, A.1
-
18
-
-
33645093204
-
QT PRODACT: In vivo QT assay in anesthetized dog for detecting the potential for QT interval prolongation by human pharmaceuticals
-
DOI 10.1254/jphs.QT-A3
-
Tashibu, H., Miyazaki, H., Aoki, K., Akie, Y. and Yamamoto, K. (2005). QT PRODACT: in vivo QT assay in anesthetized dog for detecting the potential for QT interval prolongation by human pharmaceuticals. J. Pharmacol. Sci. 99, 473-486. (Pubitemid 44618148)
-
(2005)
Journal of Pharmacological Sciences
, vol.99
, Issue.5
, pp. 473-486
-
-
Tashibu, H.1
Miyazaki, H.2
Aoki, K.3
Akie, Y.4
Yamamoto, K.5
-
19
-
-
33748086808
-
Assessing the proarrhythmic potentials of drugs: Current status of models and surrogate parameters of torsades de pointes arrhythmia
-
Thomsen M. B., Matz, J., Volders P. G. A. and Vos M. A. (2006). Assessing the proarrhythmic potentials of drugs: Current status of models and surrogate parameters of torsades de pointes arrhythmia. Pharmacol. Ther. 112, 150-170.
-
(2006)
Pharmacol. Ther.
, vol.112
, pp. 150-170
-
-
Thomsen, M.B.1
Matz, J.2
Volders, P.G.A.3
Vos, M.A.4
-
20
-
-
33645062178
-
QT PRODACT: In vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals
-
DOI 10.1254/jphs.QT-A2
-
Toyoshima, S., Kanno, A., Kitayama, T., Sekiya, K., Nakai, K., Haruna, M., Mino, T., Miyazaki, H., Yano, K. and Yamamoto, K. (2005). QT PRODACT: in vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. J. Pharmacol. Sci. 99, 459-471. (Pubitemid 44618147)
-
(2005)
Journal of Pharmacological Sciences
, vol.99
, Issue.5
, pp. 459-471
-
-
Toyoshima, S.1
Kanno, A.2
Kitayama, T.3
Sekiya, K.4
Nakai, K.5
Haruna, M.6
Mino, T.7
Miyazaki, H.8
Yano, K.9
Yamamoto, K.10
-
21
-
-
2542457330
-
Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs
-
DOI 10.1016/j.vascn.2004.03.008, PII S1056871904000164
-
Valentin, J. P., Hoffmann, P., De Clerck, F., Hammond, T. G. and Hondeghem, L. (2004). Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. J. Pharmacol. Toxicol. Methods. 49, 171-181. (Pubitemid 38686655)
-
(2004)
Journal of Pharmacological and Toxicological Methods
, vol.49
, Issue.3
, pp. 171-181
-
-
Valentin, J.-P.1
Hoffmann, P.2
De Clerck, F.3
Hammond, T.G.4
Hondeghem, L.5
-
22
-
-
50249105403
-
Early clinical development: Evaluation of drug-induced torsades de pointes risk
-
Vik, T., Pollard, C. and Sager, P. (2008). Early clinical development: Evaluation of drug-induced torsades de pointes risk. Pharmacol. Ther. 119, 210-214.
-
(2008)
Pharmacol. Ther.
, vol.119
, pp. 210-214
-
-
Vik, T.1
Pollard, C.2
Sager, P.3
-
23
-
-
0036234833
-
Towards a drug concentration effect relationship for QT prolongation and torsades de pointes
-
Webster, R., Leishman, D. and Walker, D. (2002). Toward a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr. Opin. Drug Discov. Devel. 5, 116-126. (Pubitemid 34453249)
-
(2002)
Current Opinion in Drug Discovery and Development
, vol.5
, Issue.1
, pp. 116-126
-
-
Webster, R.1
Leishman, D.2
Walker, D.3
-
24
-
-
48149096544
-
Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model
-
Yao, X., Anderson, D. L., Ross, S. A., Lang, D. G., Desai, B. Z., Cooper, D. C., Wheelan, P., McIntyre, M. S., Bergquist, M. L., MacKenzie, K. I., Becherer, J. D. and Hashim, M. A. (2008). Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model. Br. J. Pharmacol. 154, 1446-1456.
-
(2008)
Br. J. Pharmacol.
, vol.154
, pp. 1446-1456
-
-
Yao, X.1
Anderson, D.L.2
Ross, S.A.3
Lang, D.G.4
Desai, B.Z.5
Cooper, D.C.6
Wheelan, P.7
McIntyre, M.S.8
Bergquist, M.L.9
MacKenzie, K.I.10
Becherer, J.D.11
Hashim, M.A.12
|